Scarica l'app Stockscreener
20.89
1.65%
-0.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CPRX Giù?
Forum
Previsione
Precedente Chiudi:
$21.26
Aprire:
$21.23
Volume 24 ore:
421.31K
Relative Volume:
0.29
Capitalizzazione di mercato:
$2.56B
Reddito:
$460.48M
Utile/perdita netta:
$142.80M
Rapporto P/E:
17.70
EPS:
1.18
Flusso di cassa netto:
$221.79M
1 W Prestazione:
+0.43%
1M Prestazione:
+4.19%
6M Prestazione:
-5.77%
1 anno Prestazione:
-3.51%
Intervallo 1D:
$20.85
$21.27
Intervallo di 1 settimana:
$19.90
$21.29
Portata 52W:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Nome
Catalyst Pharmaceuticals Inc
Settore
Industria
Telefono
(305) 529-2522
Indirizzo
355 ALHAMBRA CIRCLE, CORAL GABLES
Confronta CPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
20.91 | 2.49B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.06 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
485.95 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.37 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
831.04 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
317.54 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-03-14 | Iniziato | Citigroup | Buy |
| 2024-03-07 | Iniziato | BofA Securities | Buy |
| 2023-12-21 | Iniziato | Oppenheimer | Outperform |
| 2022-08-24 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Ripresa | Piper Jaffray | Overweight |
| 2016-10-05 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Reiterato | ROTH Capital | Buy |
| 2014-09-16 | Reiterato | ROTH Capital | Buy |
| 2014-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2013-10-21 | Reiterato | Aegis Capital | Buy |
| 2013-09-24 | Iniziato | Maxim Group | Buy |
| 2013-09-06 | Reiterato | Aegis Capital | Buy |
| 2013-04-18 | Iniziato | Aegis Capital | Buy |
| 2012-08-27 | Aggiornamento | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Aggiornamento | Merriman | Sell → Neutral |
| 2009-05-29 | Downgrade | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Iniziato | Merriman Curhan Ford | Buy |
| 2007-11-28 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Iniziato | Stifel Nicolaus | Buy |
| 2007-01-05 | Iniziato | First Albany | Buy |
Mostra tutto
Catalyst Pharmaceuticals Inc Borsa (CPRX) Ultime notizie
Is Catalyst Pharmaceuticals Inc. stock bottoming outJuly 2025 Sentiment & Long-Term Safe Investment Plans - newser.com
What institutional flow reveals about Catalyst Pharmaceuticals Inc.Quarterly Profit Review & Real-Time Buy Signal Notifications - newser.com
Why Catalyst Pharmaceuticals Inc. stock is favored by pension fundsWeekly Volume Report & Entry and Exit Point Strategies - newser.com
Using flow based indicators on Catalyst Pharmaceuticals Inc.July 2025 Market Mood & Advanced Technical Analysis Signals - newser.com
How to use Fibonacci retracement on Catalyst Pharmaceuticals Inc.Market Risk Summary & Daily Market Momentum Tracking - newser.com
Catalyst Pharmaceuticals Shares Climb as New Drug Developments Spark Fresh Valuation Debate - Yahoo Finance
Can Catalyst Pharmaceuticals Inc. (CN2) stock surprise with quarterly resultsBuy Signal & Weekly Breakout Opportunity Watchlist - newser.com
Catalyst Pharmaceuticals (CPRX): Assessing Valuation on Clinical Progress and Expanding Rare Disease Pipeline - Sahm
Assessing Catalyst Pharmaceuticals’ Value After Recent Positive FDA Ruling in 2025 - Sahm
Catalyst Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Should Catalyst Pharmaceuticals’ (CPRX) Share Buyback and New Data Prompt a Fresh Look at Its Strategy? - Sahm
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - sharewise.com
Using Ichimoku Cloud for Catalyst Pharmaceuticals Inc. technicalsWatch List & Consistent Growth Equity Picks - newser.com
Published on: 2025-10-10 04:19:27 - newser.com
Will earnings trigger a reversal in Catalyst Pharmaceuticals Inc.Portfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
Catalyst Pharmaceuticals (NASDAQ:CPRX) Earns "Hold (C+)" Rating from Weiss Ratings - MarketBeat
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences - GlobeNewswire
Catalyst Pharmaceuticals to Present Research on Duchenne Muscular Dystrophy and Lambert Eaton Myasthenic Syndrome at Upcoming Scientific Conferences - Quiver Quantitative
3 Presentations: Catalyst Pharmaceuticals to present DMD & LEMS data at Oct 2025 conferences - Stock Titan
Real time breakdown of Catalyst Pharmaceuticals Inc. stock performance2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
Catalyst Pharmaceuticals Delivers Growth But Faces Narrow Pipeline Risk - Finimize
Published on: 2025-10-09 00:54:28 - newser.com
Lambert Eaton Myasthenic Syndrome Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Jacobus Pharmaceutical, Catalyst Pharmaceuticals - Barchart.com
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
What do Analysts Think About Catalyst Pharmaceuticals (CPRX)? - MSN
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis: Significant Upside Potential with 65% Growth Projection - DirectorsTalk Interviews
14 Biotech Stocks with High Potential - Insider Monkey
Will Catalyst Pharmaceuticals Inc. rebound enough to break evenTrade Risk Assessment & Daily Technical Forecast Reports - newser.com
Published on: 2025-10-06 05:08:49 - newser.com
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After $200 Million Share Buyback Announcement - Yahoo Finance
Detecting price anomalies in Catalyst Pharmaceuticals Inc. with AIEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com
A Closer Look at Catalyst Pharmaceuticals (CPRX) Valuation as Shares Remain Steady This Week - Sahm
Order flow analysis tools used on Catalyst Pharmaceuticals Inc.Weekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Wealth Enhancement Advisory Services LLC Lowers Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX - Defense World
Wall Street Zen Downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Hold - MarketBeat
Why Catalyst Pharmaceuticals Inc. (CN2) stock could break out in 2025July 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - newser.com
Catalyst Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
What macro factors could drive Catalyst Pharmaceuticals Inc. (CN2) stock higherPortfolio Update Report & Weekly High Conviction Trade Ideas - newser.com
Published on: 2025-10-03 06:09:02 - newser.com
Historical volatility pattern of Catalyst Pharmaceuticals Inc. visualizedJuly 2025 Breakouts & Reliable Price Breakout Alerts - newser.com
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy - The Manila Times
Catalyst Pharmaceuticals Inc Azioni (CPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Catalyst Pharmaceuticals Inc Azioni (CPRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Elsbernd Brian | Chief Compliance/Legal Officer |
Sep 08 '25 |
Sale |
20.30 |
30,000 |
609,000 |
271,039 |
3.67%
1.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):